Introduction
The lymphatic system is involved in the maintenance of the body fluid balance (Dongaonkar et al., 2009) , in immune cell trafficking (specifically in dendritic cell trafficking from tissues to lymph nodes; Miteva et al., 2010; Randolph et al., 2005) , and in dietary lipid absorption from the intestine via the blind-ended central lymph vessels in the intestinal villi known as lacteals (Iqbal and Hussain, 2009 ). Similar to the blood vasculature (Aird, 2012) , there is substantial heterogeneity and plasticity within the lymphatic system. Developmental age, function and location of lymphatic vessels are reflected in their molecular setup (Ulvmar and Mäkinen, 2016) . Lymphatic research has entered the molecular era more than two decades ago with the discovery of the first lymphangiogenic growth factor VEGF-C and its receptor VEGFR-3 (Kaipainen et al., 1995) , which was also used as the first lymphatic-specific marker. The interest in lymphatic research has been increasing since due to the recognition that lymphatics are integral to many disease processes (Alitalo, 2011) . However, the continuing discoveries of molecules that play important roles for lymphatic biology underline that our understanding of the molecular mechanisms of lymphatic development and function under both physiological and pathological settings is far from complete.
Transcription factors SOX18, COUP-TFII, PROX1 and FOXC2
The SOX18 transcription factor is perhaps the earliest involved in the specification of endothelial cells into the lymphatic lineage. It activates the expression of PROX1 (Prospero Homeobox 1) in endothelial cells of the cardinal veins around mouse embryonic day (E)9.5 (Francois et al., 2008) . SOX18 cannot activate PROX1 alone, but needs cooperation from COUP-TFII, which is expressed throughout the venous system (Srinivasan et al., 2007) . Contrary to SOX18 expression, which appears to be needed only for the initiation of LEC specification, COUP-TFII and PROX1 continue to be strongly expressed in established lymphatic vessels (Francois et al., 2011) , although only PROX1, but not COUP-TFII is necessary for the maintenance of the lymphatic identity (Johnson et al., 2008; Lin et al., 2010) .
PROX1 is expressed by several cell types like liver cells and many stem cells, but in the vascular compartment, it is largely specific for lymphatic endothelial cells, although it can be found in some specialized subpopulations of endothelial cells, e.g. in the venous (Bazigou et al., 2011) and the cardiac (Rodriguez-Niedenführ et al., 2001) valves. PROX1 is the key transcription factor for the early steps of LEC differentiation from the embryonic veins (Wigle and Oliver, 1999) and remains required for lymphatic identity (Johnson et al., 2008) . The over-expression of PROX1 in BECs modifies their expression patterns to resemble LECs (Hong et al., 2002; Petrova et al., 2002) , including the upregulation of the gene encoding VEGFR-3, that is seen in the cardinal vein endothelial cells which are committed to LEC differentiation (Wigle et al., 2002) .
The FOXC2 transcription factor becomes important during later stages of the lymphatic development. It controls the interaction between pericytes and LECs , and is required together with NFATc1 for the lymphatic remodeling and maturation including the formation of lymphatic valves in the precollectors and collectors (Norrmén et al., 2009 ).
The major mitogenic receptor on LECs: VEGFR-3
VEGFR-3 (previously also called FLT4) is the quintessential lymphatic receptor tyrosine kinase. However, early developing blood vessels (E8 to E10) also express significant amounts of VEGFR-3. In mice, loss of VEGFR-3 leads to embryonic death at E10.5 due to cardiovascular defects (Dumont et al., 1998) . Unlike VEGFR-3 deletion, the simultaneous deletion of both VEGFR-3 ligands (VEGF-C and VEGF-D) in mouse embryos does not, for the most part, affect blood vessels, with the exception of VEGF-C-induced BEC migration, which is important for the development of the coronary vasculature (Chen et al., 2014a,b) . Nevertheless, most of the early embryonic function of VEGFR-3 does apparently not require activation by ligands of the VEGF family (Haiko et al., 2008) . Hence it remains unclear, what mechanism underlies the need for VEGFR-3 in the development of the cardiovascular system. Heterodimerization with VEGFR-2 in response to VEGF-A (Dixelius et al., 2003; Nilsson et al., 2010) could enable VEGFR-3 signaling, but ligandless baseline signaling or alternative activation mechanisms involving integrins and mechanoinduction could also play a role (Galvagni et al., 2010; Planas-Paz et al., 2012; Wang et al., 2001) .
VEGFR-3 expression declines on BECs during the period of lymphatic budding from venous endothelium and the establishment of the first lymphatic structures, which starts around E10-E10.5. By day 14.5, it is seen mostly on lymphatics (Kaipainen et al., 1995) with the exception of a few vascular specializations, where it persists into adulthood, such as fenestrated vessels (Partanen et al., 2000) and some high endothelial venules (Kaipainen et al., 1995) . Mutations in Flt4 cause Type IA hereditary lymphedema (Milroy disease), which is the most common form of primary lymphedema in humans. Most of these mutations inactivate the tyrosine kinase activity of VEGFR-3 (Karkkainen et al., 2000) and in mice, functionally analogous mutations result as well in a lymphedema phenotype ).
Both LECs and BECs express VEGFR-2
VEGFR-2 is the tyrosine kinase receptor, which mediates most -if not all -functions of the classic hemangiogenic growth factor VEGF-A (Simons et al., 2016) . However, VEGFR-2 can also be activated by the mature forms of VEGF-C and VEGF-D (the different forms of VEGF-C and VEGF-D are discussed in the paragraph VEGF-D is a dissimilar twin of VEGF-C and the following). Because VEGFR-2 is also expressed at moderate levels on most LECs, VEGF-A replaces VEGF-C as medium supplement in many LEC culture protocols (Lonza, 2017; PromoCell, 2017) . Lymphatic hyperplasia has been induced by VEGF-A Wirzenius et al., 2007) and by the VEGFR-2-monospecific VEGF-E (Wirzenius et al., 2007) . Despite lymphatic hyperplasia, there was no increase in lymphatic numbers in VEGF-E overexpressing mice and in mouse ears transduced with a VEGF-A-expressing adenovirus. This led to the hypothesis that VEGFR-2 signalling causes only circumferential growth of lymphatic vessels, while VEGFR-3 signalling causes the generation of new vessels by sprouting lymphangiogenesis. VEGF-A-induced lymphangiogenesis might also be indirectly mediated by upregulating VEGF-C expression in BECs (Skobe et al., 1999; Skobe and Detmar, 2000) or in macrophages (Harvey and Gordon, 2012) , which can be recruited e.g. by VEGF-A via VEGFR-1 (Hiratsuka et al., 1998) . However, it remains unclear which mechanisms are involved in vivo.
VEGF-C is the primary lymphangiogenic growth factor
VEGF-C is the primary ligand that activates VEGFR-3 (see Fig. 1 ). The sprouting of endothelial cells from the embryonic veins is crucially dependent on VEGF-C. Its absence leads to the failure of lymph sac formation and embryonic death around E16.5 (Hagerling et al., 2013; Karkkainen et al., 2004) . Also in the heterozygous state, VEGF-C deficiency leads neonatally to severe complications due to insufficient lacteal function and resulting chylous ascites (Karkkainen et al., 2004) . Although rare, mutations in the human VEGFC gene have been shown to be responsible for some forms of hereditary lymphedema (Balboa-Beltran et al., 2014; Gordon et al., 2013) . VEGF-C is first produced in larger amounts in regions juxtaposed to the prospective locations of lymphatic sprouting (e.g. the mesenchyme around the developing metanephros and in the jugular area; Karkkainen et al., 2004; Kukk et al., 1996) and forms perhaps a gradient, along which the LECs are migrating (Jha et al., 2017; Yang and Oliver, 2014) . However, direct evidence of a VEGF-C gradient formation is lacking, and it is also still unknown how VEGF-C expression is induced.
Some lymphatic networks are not generated by lymphangiogenesis (the growth of lymphatics from pre-existing vessels), but instead by lymphvasculogenesis (the differentiation and assembly from non-venous precursor cells). Lymphvasculogenesis appears to be used in different organs and by different organisms to various degrees, but at least in mice, the lymphvascularization of the heart (Klotz et al., 2015) , the mesentery and the skin involves lymphvasculogenesis. The molecular orchestration of this process is under investigation, and similar to lymphangiogenesis, VEGF-C appears to be required.
VEGF-D is a dissimilar twin of VEGF-C
Together with VEGF-D (Achen et al., 1998) , which had been first described as c-fos-induced growth factor (FIGF) (Orlandini et al., 1996) , VEGF-C forms a subgroup within the protein family of vascular endothelial growth factors. Unlike the other VEGFs, both VEGF-C and VEGF-D are produced as pro-proteins and require a multistep proteolytic cleavage before they become active. The first (C-terminal) cleavage is similarly executed for both VEGF-C and VEGF-D by furin or the proprotein convertases PC5 and PC7 (McColl et al., 2007; Siegfried et al., 2003) . While the first cleavage is constitutive, the second (N-terminal) cleavage is tightly regulated and depends on different enzymes for VEGF-C and VEGF-D (Bui et al., 2016) .
Both VEGF-C and VEGF-D appear similarly lymphangiogenic in a variety of models like transgenic mice Veikkola et al., 2001) , adenoviral transduction of skeletal muscle (Rissanen et al., 2003) and the CAM assay (Jeltsch et al., 2003; Oh et al., 1997) . However, unlike Vegfc, Vegfd can be deleted, at least in mice, without appreciable consequences for the lymphatic system during embryogenesis (Baldwin et al., 2005) . However, adult Vegfd-deleted mice present with initial dermal lymphatics of reduced size and functionality, implying a role of VEGF-D during adult lymphangiogenesis, specifically perhaps during wound healing (Paquet-Fifield et al., 2013) . In several in vivo models, VEGF-D shows a stronger and distinct angiogenic effect compared to VEGF-C (Duong et al., 2014; Leppanen et al., 2011; Song et al., 2007; Rissanen et al., 2003) . This agrees with data showing that the maximally processed form of VEGF-D does -differently to VEGF-C -not anymore activate VEGFR-3, but only the angiogenic receptor VEGFR-2 (Leppanen et al., 2011) . The difference between VEGF-C and VEGF-D has been pinpointed to a diverging role of the N-terminal ␣-helix for receptor binding (Davydova et al., 2016) . However, many of these binding studies have been performed with truncated and/or mutated forms of VEGF-D, making it difficult to extrapolate to the in-vivo situation. Similarly, in 293EBNA cells, processing of VEGF-D results in 2.5 times more of the VEGFR-3-binding form compared to the VEGFR-2-binding form (Stacker et al., 1999) , but it is completely unknown whether and how much of the VEGFR-2-specific form is generated in vivo.
VEGF-C activation requires CCBE1 and ADAMTS3
During development, a disintegrin and metalloproteinase with thrombospondin motifs 3 (ADAMTS3) is indispensable for the proteolytic activation of pro-VEGF-C, resulting in the mature, active VEGF-C (Jeltsch et al., 2014) . ADAMTS3 was originally assumed to be a procollagen II processing enzyme (Fernandes et al., 2001 ), but Adamts3-deleted mice do not show procollagen processing defects, but instead a prenatally lethal edema phenotype (Janssen et al., 2015) . VEGF-C cleavage by ADAMTS3 requires the collagen-and calcium-binding EGF domains 1 (CCBE1) protein (Bos et al., 2011; Bui et al., 2016; Jeltsch et al., 2014; Le Guen et al., 2014) and mutations in the CCBE1 gene can be responsible for Hennekam Syndrome, a human hereditary condition characterized by generalized lymphedema (Alders et al., 2013 (Alders et al., , 2009 ). Recent studies have delineated details of the molecular requirement of CCBE1 for ADAMTS3 function and shown that also ADAMTS3 mutations can be the cause of hereditary lymphedema conditions Jha et al., 2017) . Differently to VEGF-C, VEGF-D is not activated by ADAMTS3/CCBE1 (Bui et al., 2016; Jeltsch et al., 2014) , but instead by plasmin, indicating that VEGF-D would rather act during inflammation-or wound-healing associated lymphangiogenesis (Bui et al., 2016) .
Differences between human and murine VEGFR-3 signaling
The first cDNA of VEGFC was isolated from a human library . While the early confirmations of its lymphatic function used human proteins Oh et al., 1997) , most experimental studies about the lymphatic system are performed nowadays in mice. Therefore, it is important to highlight distinct differences between the molecular interactions of the human and the corresponding murine molecules of the VEGFR-3 signaling pathway. While mature human VEGF-D can bind to both human VEGFR-2 and human VEGFR-3, mature mouse VEGF-D has been reported to bind only to mouse VEGFR-3, but not to mouse VEGFR-2 (see Fig. 1 ) (Baldwin et al., 2001) . A similarly important difference exists for VEGFR-3. Humans have two functionally diverging splice isoforms: VEGFR-3s (short isoform) and VEGFR3l (long isoform). This diversity has not been seen so far in any other non-primate species (Hughes, 2001 ). However, it remains speculative whether these dissimilarities result in morphological or functional differences.
Unorthodox VEGF-C signaling
While lymphatics and VEGF-C expression can be found in almost all tissues during development, not all VEGF-C/VEGFR-3 signaling targets endothelial cells. During brain development, neuronal progenitor cells in the olfactory bulb and glial precursor cells in the optic nerve respond to VEGF-C exposure with proliferation (Le Bras et al., 2006) . Also in adult mice, VEGF-C signaling appears to be able to stimulate neurogenesis (Han et al., 2015) , and, in zebrafish, VEGF-C appears crucial for motor neuron axon growth (Kwon et al., 2013) . In the eye, corneal epithelial cells express VEGFR-3, where it can act as a decoy receptor removing lymphangiogenic and angiogenic factors thereby maintaining avascularity Frequently encountered growth factors, receptors and co-receptors in endothelial cell biology. Both the VEGF receptors and the TIE receptors are the major signalling receptors for endothelial cells and they are for the most part specific for endothelial cells. VEGF receptors are supported by neuropilins, integrins and heparan sulfate proteoglycan (HSPG) co-receptors, which stabilize the growth factor receptor interaction and enhance signalling. The cartoon depicts the receptor domain organization, and known ligand-receptor interactions for the VEGF receptor tyrosine kinases and neuropilin co-receptors. From the integrin and HSPG co-receptor groups, not all known interacting co-receptors are included. In addition to the mammalian growth factor ligands also snake venom VEGFs (collectively known as VEGF-F) and viral VEGFs (collectively known as VEGF-E) are shown. Ligand-receptor interactions are not always conserved between orthologs of different mammalian species. The dotted arrows indicate absent interaction in some species or for some isoforms. To enhance clarity, interaction arrows are differently colored according to receptor group. The arrows of HSPG co-receptors connects them to their interacting VEGF receptors since the direct interaction of VEGF ligand and HSPG has not been shown in all cases. All VEGFs are -as well as the VEGF-C activators CCBE1 and ADAMTS3 -ill-suited as marker molecules due to their secreted nature. Note, that the short isoform of VEGFR-3 (VEGFR-3s) has been seen so far only in higher primates including humans. Modified from Wikimedia Commons. (Cursiefen et al., 2006) . Unsurprisingly, due to their common ancestry, quite a few cells of hematopoietic origin express VEGFR-3 and react to VEGF-C. Such cells include hematopoietic stem cells (Fang et al., 2016; Hamada et al., 2000) and megakaryocyte precursors (Thiele et al., 2012) . The expression of VEGFR-3 by corneal dendritic cells (Hamrah et al., 2003) and by conjunctival cells of the monocyte/macrophage lineage (Hamrah et al., 2004) has been suggested to play a role for the immune response in the eye. Macrophages not only can express VEGFR-3, but they also can secrete the VEGFR-3 ligand VEGF-C. In the skin, macrophages intriguingly appear to regulate the salt balance of body fluids by secreting VEGF-C, which in turn has been proposed to regulate the lymphatic volume and gateway function between the hyperosmotic interstitium and normosmolar blood (Machnik et al., 2009 ). VEGFR-3 can also be expressed by tumor associated macrophages (Schoppmann et al., 2002) ; and VEGF-C reportedly enhances tumor cell metastasis (Su et al., 2006) and leukemic cell growth and proliferation (Dias et al., 2002) by signaling through the VEGFR-3 present on the tumor cells. However, this notion has been challenged for solid tumors. Poor antibody specificity is likely responsible for most of the VEGFR-3 signals from tumor cells, while true-positive VEGFR-3 signals originate predominantly from endothelial cells (Petrova et al., 2008; Smith et al., 2010) , where VEGFR-3 signaling promotes both tumor angiogenesis (Tammela et al., 2008) and tumor lymphangiogenesis (Mandriota et al., 2001; Karpanen et al., 2001; Skobe et al., 2001) , which results in increased metastasis.
Co-receptors
Neuropilin-1 (NRP1) and neuropilin-2 (NRP2) have been first described as transmembrane proteins of neuronal cells, in which they regulate the growth of dendrites and axons together with their different semaphorin ligands, which act either as attractants or repellents (Schwarz and Ruhrberg, 2010) . Both NRP1 and NRP2 are also expressed by endothelial cells, with NRP1 more prominently on arteries and NRP2 more prominently on LECs and veins (Herzog et al., 2001; Yuan et al., 2002) . They act as co-receptors for VEGF ligands by stabilizing the growth factor/receptor complex, but likely do not exercise a signaling function in endothelial cells (Guo and Vander Kooi, 2015) . While virtually all VEGF family members have been seen to interact with NRP1 (and most with NRP2), the VEGF-A/NRP1 (Kawamura et al., 2008) and the VEGF-C/NRP2 ) interactions appear to be significant both in vivo and in vitro (Karpanen et al., 2006) . Similar to the neuropilins, ␣5␤1 integrin (Wang et al., 2001; Zhang et al., 2005) and syndecan-4 (Johns et al., 2016) are known co-receptors for VEGFR-3. They can enrich the effective cell surface concentration of VEGF-C, stabilize the receptor interaction of VEGF-C and render VEGFR-3 signaling pressure-sensitive (Planas-Paz et al., 2012) . Similarly, VEGFR-2 signalling can be enhanced by interaction with ␣v␤3 integrin (Soldi et al., 1999) and perlecan (Zoeller et al., 2009 ).
LYVE-1 and podoplanin
When endothelial structures are immunohistochemically interrogated, the expression of the cell surface glycoproteins LYVE-1 and podoplanin (PDPN) are good indicators of lymphatic nature. Apart from LECs, LYVE-1 is expressed also on liver BECs (Carreira et al., 2001 ) and on certain macrophages (Schledzewski et al., 2006) , but it is generally a useful marker to identify lymphatic capillaries (Banerji et al., 1999) . LYVE-1 expression is decreased on lymphatic pre-collectors and absent from collectors (Lutter et al., 2012) . LYVE-1 is a receptor for hyaluronic acid and functions in dendritic cell entry into the lymphatics (Johnson et al., 2017) . Similar to LYVE-1, PDPN is frequently used in the immunohistochemical detection of lymphatics (Breiteneder-Geleff et al., 1999) . PDPN was originally identified from cells of the osteoblastic lineage (Wetterwald et al., 1996) and podocytes, where it is important for the formation of the glomerular filtration barrier of the kidney (Matsui et al., 1999) . PDPN is not required for the early steps of lymphatic development and is e.g. also absent from the first LECs that emigrate from the cardinal veins (initial LECs or iLECs; see Fig. 2) (Hagerling et al., 2013) . Key and marker molecules in the development of the lymphatic system. In mice, expression of SOX18 and COUP-TFII in the embryonic veins induces PROX1 expression at around E9.5 in a subset of venous endothelial cells. PROX1-expressing lymphatic progenitor cells are specified to become lymphatic endothelial cells. PROX1-expressing venous endothelial cells (shown in purple) emigrate upon VEGFR-3-mediated VEGF-C signals. These initial LECs (iLECs, shown in red) assemble into the earliest lymphatic structures ("lymph sacs", shown in olive), which mature and expand to form a hierarchical lymphatic vascular network with capillaries (in green) and collecting vessels (in cyan). The yellow parts of the lymphatic network are not of venous origin: for a long time, it was thought, that lymphatics develop exclusively from the venous-derived early lymphatic structures by sprouting lymphangiogenesis. However, there is substantial evidence that e.g. the mesenteric lymphatic network is assembled from differentiating, non-venous precursors (lymphvasculogenesis) . In the skin, both sprouting and differentiation mechanisms seem to contribute to lymphvascularization . The ruler indicates the approximate starting times of the main developmental events in days of mouse embryonic development, but there are both significant spatial differences and temporal overlaps. The color labeling of the developmental events refers to the main LEC population(s) involved. (For interpretation of the references to color in the text, the reader is referred to the web version of this article.) PDPN rather appears to play a later role in lymphatic patterning and separation from the blood vasculature (Bertozzi et al., 2010; Uhrin et al., 2010) .
Angiopoietin-TIE system
The ANG/TIE system is an important signaling component controlling endothelial cell behavior in both angiogenesis and lymphangiogenesis. Like the VEGF receptors, TIE receptor expression is mostly restricted to endothelial cells with the notable exception of some hematopoietic cells (Batard et al., 1996) . No ligand has been identified for TIE1 and it is thus considered to be an orphan receptor. It contributes to signaling in concert with TIE2, which is the receptor for all known angiopoietins (see Fig. 1 ). Genetic targeting of Tie1 is embryonically lethal and shows lymphatic abnormalities resulting in edema which arises from dysregulated lymph sac formation (D'Amico et al., 2010) , defects in lymphatic vessel remodeling, collecting vessel formation and valve morphogenesis (Shen et al., 2014; Qu et al., 2015) . In adult mice, however, Tie1 ablation is well tolerated (D'Amico et al., 2014) . Deletion of Ang2 results in defective collecting lymphatic vessel formation (Dellinger et al., 2008) and a smaller diameter of lymphatic capillaries without any noticeable effect in the early lymphatic development (Shen et al., 2014) . Interestingly, Ang1 can rescue the lymphatic abnormalities observed in the Ang2 deleted mice (Dellinger et al., 2008) . However, no apparent effect on lymphatic vasculature is observed in the Tie2 deleted mice (Shen et al., 2014) .
ANG ligands can signal in two different configurations. The TIE receptors from two cells in close proximity can become ligated by ANG ligands (trans complexes). Alternatively, TIE receptors can form complexes within one cell triggered by e.g. matrix-bound ANG ligands (cis complexes) (Fukuhara et al., 2008; Saharinen et al., 2008) . This, and the fact that ANG2 is a partial agonist (Yuan et al., 2009) demonstrate, that the biological response within the ANG/TIE signaling is complex and context-dependent (reviewed by Eklund et al., 2017) .
Conclusions
While the growing interest in lymphatic research has spawned many searches for "lymphatic" molecules Nelson et al., 2007; Petrova et al., 2002) , the recent discovery of the essential functions of CCBE1 and ADAMTS3 for lymphatic development shows that we likely have not yet identified all important molecules in this field and that some surprises still lie ahead. This minireview is focused on the most central molecules (summarized in Table 1 ) skipping many essential molecules like those for the interaction of LECs with cells of the immune system (e.g. CCL21 for dendritic cell migration) (Russo et al., 2016; Vaahtomeri et al., 2017a; Weber et al., 2013) and those for pathological lymphan- Table 1 Selected key molecules in lymphatic research and their properties. Listed from top to bottom and separated by background color are receptor tyrosine kinases, other transmembrane receptors, secreted growth factors, proteases/protease cofactors and transcription factors. Astarita et al., 2012; Baluk et al., 2005; Bekhouche and Colige, 2015; Brekken et al., 1998; Caunt et al., 2008; Dumont et al., 1994; Gale et al., 2007; Jackson et al., 2001; Jussila et al., 1998; Kawasaki et al., 1999; Krebs and Jeltsch, 2013; Leow, 2012; Liang et al., 2007; Pereira et al., 1999; Prevo et al., 2001; Prewett et al., 1999; Pytowski et al., 2005; Saharinen et al., 2017; Sato et al., 1995; Shalaby et al., 1995; Stacker and Achen, 2018; Ugorski et al., 2016; Winnier et al., 1997; Winnier et al., 1999; Zhu et al., 1998; Zou et al., 2013) Mice die between E10 and E12.5 due to abnormal vascular development and growth retardation (Dumont et al., 1998) Anti-human VEGFR-3 (mouse monoclonal, clone 9D9F9, Jussila et al., 1998) , anti-human VEGFR-3 (goat polyclonal, AF349, R&D Systems), antimouse VEGFR-3 (goat polyclonal, AF743, R&D Systems) mF4-31C1 VGX-300/OPT-302, IMC-3C5 Vascular endothelial growth factor receptor-2 VEGFR-2 KDR, Flk-1, CD309 KDR Receptor for VEGF-A, VEGF-C, VEGF-D Isoform 1, mbVegfr-2; isoform 2, sVegfr-2; isoform 3, VEGFR2-712
Capillary infantile hemangioma (602089) Mice die between E8.5 and E9.5 due to reduction in hematopoietic progenitors and impaired vasculogenesis (Shalaby et al., 1995) Anti-human VEGFR-2 (rabbit monoclonal, #2479, Cell Signaling Technology), anti-human VEGR-2 (goat polyclonal, AF357, R&D Systems), antimouse VEGFR-2 (goat polyclonal, AF644, R&D Systems) DC101 (Prewett et al., 1999) , ScFv P1C11 (Zhu et al., 1998) , 2C3 (Brekken et al., 1998) Axitinib, Tivozanib, Cediranib Death at >= E13.5 because of hemorrhages, lymphatic vessel defects, edema, endothelial integrity, reduced atherosclerosis and tumor growth (D'Amico et al., 2010; Sato et al., 1995) Anti-human TIE1 (goat polyclonal, AF619, R&D Systems) (617272) Death at E9.5-E10.5, reduced myocardial growth, lymphatic vessel defects when deleted at E12.5 but no effect when deleted at E7 (Dumont et al., 1994; Shen et al., 2014) Anti-human TIE2 (goat polyclonal, AF313, R&D Systems) Mice die prenatally at E10.5, vascular regression in embryos (Kawasaki et al., 1999) Anti-human Neuropiln-1 (goat polyclonal, C-19, sc-7239, Santa Cruz) YW107.4.87 (Liang et al., 2007) Neuropilin-2 NRP2 NP-2, NRP-2 NRP2 Co-receptor for VEGF-A and VEGF-C Isoform A22; isoform A0; isoform A17; isoform B0; isoform B5; isoform s9
VEGF-A ,VEGF-A ,PIGF-2,Semaphorins 3C and 3F
Mice are viable, small lymphatic vessels and capillaries are reduced in size (Yuan et al., 2002) Anti-human Neuropilin-2 (rabbit polyclonal, H-300, sc-5542, Santa Cruz) Anti-Nrp2B (Caunt et al., 2008) Lymphatic vessel endothelial hyaluronic acid receptor 1
LYVE-1
Cell surface retention sequencebinding protein 1 (CRSBP-1), Extracellular link domain-containing protein 1
LYVE1
Receptor for hyaluronic acid No obvious phenotype (Gale et al., 2007) Anti-mouse LYVE-1 (rabbit antiserum) , anti-mouse LYVE-1 (rat monoclonal, MAB2125, R&D Systems), anti LYVE-1 (rabbit polyclonal, ab14917, abcam)
Anti-LYVE-1 (11-034, AngioBio)
Podoplanin PDPN Aggrus, Glycoprotein 36 (Gp36), PA2.26 antigen, T1-alpha (T1A)
PDPN

Ligand for CLEC1B
Isoform 1, hT1alpha-2; isoform 2, hT1alpha-1; isoform 3; isoform 4; isoform 5; isoform 6 CLEC1B (Astarita et al., 2012; Ugorski et al., 2016) Mice die after birth as a result of respiratory failure, reduced lymphatic transport, lymphedema, dilation of lymphatic vasculature Anti-human podoplanin (mouse monoclonal, clone D2-40, Covance), antimouse podoplanin (syrian hamster, monoclonal, clone 8. Hereditary lymphedema type 1D (615907) Mice die prenatally between E15.5-E17.5, lack of lymphatic sprout formation from the cardinal vein, lymphedema (Karkkainen et al., 2004) ; defect in fetal eryhtropoiesis when deleted after E7.5 (Fang et al., 2016) Anti-human VEGF-C (goat polyclonal, AF752, R&D Systems), anti-VEGF-C #5 (Baluk et al., 2005) VGX-100 (Vegenics, Opthea Ltd, Australia) Stacker and Achen, 2018) No obvious embryonic phenotype (Baldwin et al., 2005) Anti-human VEGF-D (VD1) ; anti-human VEGF-D (goat polyclonal, AF286, R&D Systems) VD1, VD2, VD3, VD4 Angiopoietin 2 ANG2 ANGPT2 ANGPT2 Ligand for TIE2 3 isoforms TIE2 Saharinen et al., 2017) Mice die 2 weeks after birth, abnormal lymphatic modelling and postanatal angiogenesis (Dellinger et al., 2008) Anti-human Ang2 (goat polyclonal, AF623, R&D Systems) MEDI3617 (Leow, 2012) Nesvacumab, MEDI3617, Vanucizumab, RG7716
Protease
A disintegrin and metalloproteinase with thrombospondin motifs 3
ADAMTS3
Procollagen II Nproteinase (PC II-NP)
ADAMTS 3
Activation of VEGF-C VEGF-C, CCBE1 Hennekam lymphangiectasialymphedema syndrome 3
Mice die prenatally, lack of lymphatic vasculature, edema, compromised liver development (Janssen et al., 2016) Cofactor Collagen-and calcium-binding EGF domains 1
CCBE1
Protein cofactor for ADAMTS3 protease 3 isoforms ADAMTS3, Vitronectin (Vaahtomeri et al., 2017) Hennekam lymphangectasialymphedema syndrome 1 (HKLLS1, 235510)
Mice die prenatally, lack of lymphatic vasculature (Bos et al., 2011) , defective erythropoiesis in fetal liver (Zou et al., 2013) Anti-human CCBE1 (rabbit polyclonal, HPA041374, Atlas antibodies) 
FOXC2
Controls interaction between pericytes and LECs, regulates lymphatic maturation and remodelling
NFATc1
Lymphedema-distichiasis syndrome (153400)
Mice die prenatally > E13.5, cardiovascular abnormalities, some mutants can survive with skeletal abnormalities (Winnier et al., 1999 (Winnier et al., , 1997 Anti-mouse FoxC2 (Sheep polyclonal, AF6989, R&D Systems); anti-human FoxC2 (Sheep polyclonal, AF5044, R&D Systems)
Transcription factors (Francois et al., 2011) (Simons et al., 2016) Saharinen et al., 2017) Other transmembrane receptors (Guo and Vander Kooi, 2015) Secreted growth factors Receptor tyrosine kinases 165 145 giogenesis, in which VEGF-C and VEGF-D are activated differently compared to developmental lymphatic growth (Bui et al., 2016; McColl et al., 2003) . The designation of the LEC markers and the identification of lymphatic vessels are not without pitfalls. While the expression of commonly used LEC markers (VEGFR-3, PROX1, LYVE-1, PDPN) is largely restricted to LECs unlike the expression of general endothelial markers like PECAM-1 (CD31) (Parums et al., 1990; Sawa et al., 1998) or VE-cadherin (Baluk et al., 2007; Lampugnani et al., 1992) , none of them is entirely exclusive for LECs. Unequivocal identification of lymphatic vessels requires therefore a combination of markers, and guidelines have been published, e.g. for the lymphatics of the human eye (Schrödl et al., 2015; Schroedl et al., 2014) . To identify not only lymphatic structures but also their subtypes such as collector, valve and capillary, marker molecules are normally used in combination. E.g. LYVE-1 and podoplanin are frequently used LEC surface markers, which show a heterogeneous expression depending on the vessel caliber.
The list of molecules with a lymphatic connection will continue to grow over the next years. From the medical perspective, almost every molecule in that list, once sufficiently understood, represents a possibility for therapeutic intervention. A few promising interventions are ongoing at the pharmaceutical level (Eiger BioPharmaceuticals, 2016; Herantis Pharma Plc, 2016) . Beyond these, the growing precision of genome editing tools might in the future open the door for the correction of hereditary lymphatic conditions.
A recent in-depth general review beyond the scope of this minireview is Vaahtomeri et al. (2017b) . Additionally, several review articles treat specific focus areas like the relationship of lymphatics with the cardiovascular system (Aspelund et al., 2016) , the embryonic development of the lymphatic system (Koltowska et al., 2013) , lymphatic tissue engineering (Schaupper et al., 2016) , lymphatic diseases (Wang and Oliver, 2010) , therapeutic prospects (Zheng et al., 2014) , and VEGF-C (Rauniyar et al., 2018) .
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